Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gastric intestinal metaplasia and tamoxifen: can we reverse the inevitable?

Literature DB >> 24595657

Gastric intestinal metaplasia and tamoxifen: can we reverse the inevitable?

James R Goldenring¹.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Tamoxifen

Year: 2014 PMID： 24595657 DOI： 10.1007/s10620-014-3088-4

Source DB: PubMed Journal: Dig Dis Sci ISSN： 0163-2116 Impact factor: 3.199

× No keyword cloud information.

11 in total

1. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer.

Authors: James R Goldenring; Ki Taek Nam; Timothy C Wang; Jason C Mills; Nicholas A Wright
Journal: Gastroenterology Date: 2010-05-05 Impact factor: 22.682

2. Predictive factors for improvement of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication: a three-year follow-up study in Korea.

Authors: Jung Mook Kang; Nayoung Kim; Cheol Min Shin; Hye Seung Lee; Dong Ho Lee; Hyun Chae Jung; In Sung Song
Journal: Helicobacter Date: 2012-04 Impact factor: 5.753

3. Prostaglandin E₂ signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors.

Authors: Hiroko Oshima; Kyoji Hioki; Boryana K Popivanova; Keisuke Oguma; Nico Van Rooijen; Tomo-O Ishikawa; Masanobu Oshima
Journal: Gastroenterology Date: 2010-11-09 Impact factor: 22.682

4. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast.

Authors: Ainslie B Parsons; Andres Lopez; Inmar E Givoni; David E Williams; Christopher A Gray; Justin Porter; Gordon Chua; Richelle Sopko; Renee L Brost; Cheuk-Hei Ho; Jiyi Wang; Troy Ketela; Charles Brenner; Julie A Brill; G Esteban Fernandez; Todd C Lorenz; Gregory S Payne; Satoru Ishihara; Yoshikazu Ohya; Brenda Andrews; Timothy R Hughes; Brendan J Frey; Todd R Graham; Raymond J Andersen; Charles Boone
Journal: Cell Date: 2006-08-11 Impact factor: 41.582

5. Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics.

Authors: Hyuk Yoon; Nayoung Kim; Hye Seung Lee; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Hyun Chae Jung; In Sung Song
Journal: Helicobacter Date: 2011-10 Impact factor: 5.753

6. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn?

Authors: A C de Vries; E J Kuipers; E A J Rauws
Journal: Am J Gastroenterol Date: 2009-06 Impact factor: 10.864

7. Chronic tamoxifen use is associated with a decreased risk of intestinal metaplasia in human gastric epithelium.

Authors: Chang Mo Moon; Seok-Hyung Kim; Sang Kil Lee; Jiyeon Hyeon; Ja Seung Koo; Sangheun Lee; Jean S Wang; Won Jae Huh; Shradha S Khurana; Jason C Mills
Journal: Dig Dis Sci Date: 2013-12-25 Impact factor: 3.199

8. Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.

Authors: Samy A F Morad; Jonathan C Levin; Su-Fern Tan; Todd E Fox; David J Feith; Myles C Cabot
Journal: Biochim Biophys Acta Date: 2013-08-09

9. Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia.

Authors: Takeyuki Wada; Takatsugu Ishimoto; Ryo Seishima; Kenji Tsuchihashi; Momoko Yoshikawa; Hiroko Oshima; Masanobu Oshima; Takashi Masuko; Nicholas A Wright; Satoshi Furuhashi; Kotaro Hirashima; Hideo Baba; Yuko Kitagawa; Hideyuki Saya; Osamu Nagano
Journal: Cancer Sci Date: 2013-08-12 Impact factor: 6.716

10. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention.

Authors: Yi-Chia Lee; Tony Hsiu-Hsi Chen; Han-Mo Chiu; Chia-Tung Shun; Hung Chiang; Tzeng-Ying Liu; Ming-Shiang Wu; Jaw-Town Lin
Journal: Gut Date: 2012-06-14 Impact factor: 23.059

5 in total

Gastric intestinal metaplasia and tamoxifen: can we reverse the inevitable?

1. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer.

2. Predictive factors for improvement of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication: a three-year follow-up study in Korea.

3. Prostaglandin E₂ signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors.

4. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast.

5. Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics.

6. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn?

7. Chronic tamoxifen use is associated with a decreased risk of intestinal metaplasia in human gastric epithelium.

8. Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells.

9. Functional role of CD44v-xCT system in the development of spasmolytic polypeptide-expressing metaplasia.

10. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention.

1. Changing the natural history of metachronous gastric cancer after H. pylori eradication.

Review 2. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits.

3. Intestinal Stem Cell Markers in the Intestinal Metaplasia of Stomach and Barrett's Esophagus.

Review 4. Hedgehog Signaling Links Chronic Inflammation to Gastric Cancer Precursor Lesions.

Review 5. Pathogenesis and risk factors for gastric cancer after Helicobacter pylori eradication.